Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
18.71
+0.43 (2.35%)
At close: Sep 18, 2026, 4:00 PM EDT
19.18
+0.47 (2.51%)
After-hours: Sep 18, 2026, 7:49 PM EDT
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Amneal Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $22. The average 1-year stock price forecast is 17.58% higher than the current stock price, while the lowest is $20 (+6.89%) and the highest is $25 (+33.62%).
Price Target: $22 (+17.58%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 3 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Reiterates $16 → $20 | Buy | Reiterates | $16 → $20 | +6.89% | Sep 17, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $23 | Buy | Reiterates | $23 | +22.93% | Sep 17, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $22 | Buy | Maintains | $22 | +17.58% | Aug 26, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $19 → $21 | Buy | Maintains | $19 → $21 | +12.24% | Aug 10, 2026 |
| UBS | UBS | Buy Maintains $23 → $25 | Buy | Maintains | $23 → $25 | +33.62% | Aug 3, 2026 |
Financial Forecast
Revenue This Year
3.15B
from 3.02B
Increased by 4.48%
Revenue Next Year
3.44B
from 3.15B
Increased by 9.02%
EPS This Year
1.02
from 0.83
Increased by 22.87%
EPS Next Year
1.20
from 1.02
Increased by 17.31%
EPS and Forward PE are based on non-GAAP adjusted numbers.